(ITGR) Integer Holdings - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45826H1095

Medical Devices, Cardiac Rhythm, Neuromodulation, Batteries, Orthopedics

ITGR EPS (Earnings per Share)

EPS (Earnings per Share) of ITGR over the last years for every Quarter: "2020-09": 0.5, "2020-12": 0.71, "2021-03": 0.97, "2021-06": 1.07, "2021-09": 1.05, "2021-12": 0.99, "2022-03": 0.78, "2022-06": 1.04, "2022-09": 0.95, "2022-12": 1.11, "2023-03": 0.87, "2023-06": 1.14, "2023-09": 1.27, "2023-12": 1.39, "2024-03": 1.14, "2024-06": 1.3, "2024-09": 1.43, "2024-12": 1.43, "2025-03": 1.31, "2025-06": 1.55, "2025-09": 1.79,

ITGR Revenue

Revenue of ITGR over the last years for every Quarter: 2020-09: 235.942, 2020-12: 268.959, 2021-03: 290.467, 2021-06: 312.023, 2021-09: 305.574, 2021-12: 313.015, 2022-03: 310.912, 2022-06: 350.081, 2022-09: 342.68, 2022-12: 373.195, 2023-03: 378.785, 2023-06: 399.763, 2023-09: 396.803, 2023-12: 404.504, 2024-03: 407.796, 2024-06: 427.886, 2024-09: 431.417, 2024-12: 449.497, 2025-03: 437.392, 2025-06: 476.494, 2025-09: 467.691,

Description: ITGR Integer Holdings November 08, 2025

Integer Holdings Corp (NYSE: ITGR) is a contract development and manufacturing organization (CDMO) that produces a broad portfolio of medical devices for OEM customers, covering cardiac rhythm management, neuromodulation, orthopedics, vascular, and portable-medical markets. Its operations span the United States, Puerto Rico, Costa Rica, and other international sites, serving multinational manufacturers and their subsidiaries.

Key performance indicators from the most recent fiscal year (2023) show revenue of roughly $2.2 billion, with an operating margin of about 5 % and a free-cash-flow conversion rate near 70 %. The cardiac rhythm management segment, the largest contributor, grew ~6 % YoY, reflecting continued demand for implantable pacemakers and defibrillators amid an aging U.S. population and expanding indications for heart-failure therapy.

Sector-level drivers that materially affect Integer include (1) the U.S. healthcare spending outlook, projected to rise 4-5 % annually through 2027, which sustains demand for high-margin implantable devices; (2) supply-chain pressures on specialty components such as non-rechargeable batteries, where lead times have widened 20-30 % in 2024, potentially compressing contract pricing; and (3) regulatory trends, notably the FDA’s emphasis on post-market surveillance, which can increase OEM reliance on CDMOs for compliance-ready manufacturing.

For analysts seeking a deeper quantitative view of Integer’s valuation dynamics, a quick look at ValueRay’s proprietary risk-adjusted return metrics can surface hidden upside or downside factors worth exploring.

ITGR Stock Overview

Market Cap in USD 2,404m
Sub-Industry Health Care Equipment
IPO / Inception 2000-09-29

ITGR Stock Ratings

Growth Rating -28.4%
Fundamental 67.3%
Dividend Rating -
Return 12m vs S&P 500 -55.5%
Analyst Rating 4.60 of 5

ITGR Dividends

Currently no dividends paid

ITGR Growth Ratios

Growth Correlation 3m -70.7%
Growth Correlation 12m -89.6%
Growth Correlation 5y 59.1%
CAGR 5y -1.57%
CAGR/Max DD 3y (Calmar Ratio) -0.03
CAGR/Mean DD 3y (Pain Ratio) -0.18
Sharpe Ratio 12m -1.06
Alpha -62.36
Beta 0.826
Volatility 36.81%
Current Volume 717.2k
Average Volume 20d 945.4k
Stop Loss 64.1 (-6.1%)
Signal 0.14

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (86.9m TTM) > 0 and > 6% of Revenue (6% = 109.9m TTM)
FCFTA 0.05 (>2.0%) and ΔFCFTA 2.54pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 31.04% (prev 30.37%; Δ 0.67pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.06 (>3.0%) and CFO 204.0m > Net Income 86.9m (YES >=105%, WARN >=100%)
Net Debt (1.25b) to EBITDA (356.3m) ratio: 3.51 <= 3.0 (WARN <= 3.5)
Current Ratio 3.71 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (35.6m) change vs 12m ago -0.51% (target <= -2.0% for YES)
Gross Margin 26.99% (prev 27.15%; Δ -0.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 55.78% (prev 52.77%; Δ 3.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 5.17 (EBITDA TTM 356.3m / Interest Expense TTM 45.2m) >= 6 (WARN >= 3)

Altman Z'' 3.12

(A) 0.17 = (Total Current Assets 778.1m - Total Current Liabilities 209.8m) / Total Assets 3.40b
(B) 0.28 = Retained Earnings (Balance) 945.4m / Total Assets 3.40b
(C) 0.07 = EBIT TTM 233.5m / Avg Total Assets 3.28b
(D) 0.61 = Book Value of Equity 1.01b / Total Liabilities 1.65b
Total Rating: 3.12 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 67.27

1. Piotroski 4.50pt = -0.50
2. FCF Yield 4.53% = 2.26
3. FCF Margin 9.04% = 2.26
4. Debt/Equity 0.75 = 2.23
5. Debt/Ebitda 3.51 = -2.32
6. ROIC - WACC (= 1.15)% = 1.44
7. RoE 5.21% = 0.43
8. Rev. Trend 97.33% = 7.30
9. EPS Trend 83.37% = 4.17

What is the price of ITGR shares?

As of November 08, 2025, the stock is trading at USD 68.26 with a total of 717,238 shares traded.
Over the past week, the price has changed by +5.71%, over one month by -34.19%, over three months by -35.43% and over the past year by -49.28%.

Is Integer Holdings a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Integer Holdings (NYSE:ITGR) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 67.27 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ITGR is around 50.15 USD . This means that ITGR is currently overvalued and has a potential downside of -26.53%.

Is ITGR a buy, sell or hold?

Integer Holdings has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy ITGR.
  • Strong Buy: 7
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the ITGR price?

Issuer Target Up/Down from current
Wallstreet Target Price 84.9 24.3%
Analysts Target Price 84.9 24.3%
ValueRay Target Price 54.7 -19.9%

ITGR Fundamental Data Overview November 06, 2025

Market Cap USD = 2.40b (2.40b USD * 1.0 USD.USD)
P/E Trailing = 28.2346
P/E Forward = 16.5563
P/S = 1.3129
P/B = 2.1201
P/EG = 0.6369
Beta = 0.826
Revenue TTM = 1.83b USD
EBIT TTM = 233.5m USD
EBITDA TTM = 356.3m USD
Long Term Debt = 980.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 9.12m USD (from shortTermDebt, last quarter)
Debt = 1.31b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.25b USD (from netDebt column, last quarter)
Enterprise Value = 3.66b USD (2.40b + Debt 1.31b - CCE 58.9m)
Interest Coverage Ratio = 5.17 (Ebit TTM 233.5m / Interest Expense TTM 45.2m)
FCF Yield = 4.53% (FCF TTM 165.5m / Enterprise Value 3.66b)
FCF Margin = 9.04% (FCF TTM 165.5m / Revenue TTM 1.83b)
Net Margin = 4.75% (Net Income TTM 86.9m / Revenue TTM 1.83b)
Gross Margin = 26.99% ((Revenue TTM 1.83b - Cost of Revenue TTM 1.34b) / Revenue TTM)
Gross Margin QoQ = 26.98% (prev 27.41%)
Tobins Q-Ratio = 1.08 (Enterprise Value 3.66b / Total Assets 3.40b)
Interest Expense / Debt = 0.71% (Interest Expense 9.37m / Debt 1.31b)
Taxrate = 13.73% (6.31m / 46.0m)
NOPAT = 201.5m (EBIT 233.5m * (1 - 13.73%))
Current Ratio = 3.71 (Total Current Assets 778.1m / Total Current Liabilities 209.8m)
Debt / Equity = 0.75 (Debt 1.31b / totalStockholderEquity, last quarter 1.75b)
Debt / EBITDA = 3.51 (Net Debt 1.25b / EBITDA 356.3m)
Debt / FCF = 7.56 (Net Debt 1.25b / FCF TTM 165.5m)
Total Stockholder Equity = 1.67b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.56% (Net Income 86.9m / Total Assets 3.40b)
RoE = 5.21% (Net Income TTM 86.9m / Total Stockholder Equity 1.67b)
RoCE = 8.82% (EBIT 233.5m / Capital Employed (Equity 1.67b + L.T.Debt 980.2m))
RoIC = 7.23% (NOPAT 201.5m / Invested Capital 2.79b)
WACC = 6.08% (E(2.40b)/V(3.72b) * Re(9.06%) + D(1.31b)/V(3.72b) * Rd(0.71%) * (1-Tc(0.14)))
Discount Rate = 9.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 2.36%
[DCF Debug] Terminal Value 78.21% ; FCFE base≈128.9m ; Y1≈159.0m ; Y5≈271.3m
Fair Price DCF = 109.1 (DCF Value 3.82b / Shares Outstanding 35.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 83.37 | EPS CAGR: 18.98% | SUE: 2.08 | # QB: 1
Revenue Correlation: 97.33 | Revenue CAGR: 8.55% | SUE: 0.07 | # QB: 0

Additional Sources for ITGR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle